Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT03403686
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - 98 Years
Healthy Volunteers
Accepted

Interventions

  • blood draw — BIOLOGICAL
    Blood sample will be obtained and CD34+ cells will be isolated for functional testing.

Study Details

Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to preserve the function of reparative cells while reducing inflammatory cell.

Key Dates

Start date
Jan 11, 2018
Status verified
Sep 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
104 participants (estimated)

Arms

  • Arm: Controls
    Any man or woman between the ages of 21- 98 years of age will be eligible to participate. To participate in the study as a study subject we will require that the subject must carry the diagnosis of healthy control.
  • Arm: Diabetic no retinopathy
    Patients with diabetes but with no evidence of diabetic retinopathy
  • Arm: Diabetic with mild retinopathy
    Diabetics with mild non proliferative diabetic retinopathy (NPDR).
  • Arm: Diabetic with moderate retinopathy
    Diabetics with moderate NPDR
  • Arm: Diabetics with severe retinopathy
    Diabetic with severe NPDR.
  • Arm: Diabetics with proliferative diabetic retinopathy (PDR)
    Diabetics with proliferative diabetic retinopathy (PDR)

Primary Outcome Measure

Assessing CD34+ cells function [ Time Frame: from blood draw to 48 hours ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama at BirminghamBirminghamAlabama35294
Jennifer Moorer
[email protected]
2053258674
Maria B Grant, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Birmingham, AL

By condition
Diabetic retinopathy
By specialty
OphthalmologyRetina
By research site
University of Alabama at Birmingham· Birmingham, AL

Related Studies